Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2

JAMA

Volumn 296, Issue 13, 2006, Pages 1633-1644

  McGettigan, Patricia ^a   Henry, David ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN SYNTHASE; ROFECOXIB; LACTONE; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONE;

BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HEART INFARCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; HUMANS; LACTONES; NAPROXEN; PYRAZOLES; RISK; SULFONAMIDES; SULFONES;

EID: 33749339372     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.13.jrv60011     Document Type: Review

References (44)

1. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
2. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclooxygenase inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330:1366-1372.
3. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
4. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068-2073.
5. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99:132-140.
6. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the riak of atherothrombosis? meta-analysis of randomised trials. BMJ. 2006;332:1302-1305.
7. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:413-421.
8. Bombardier C, Laine L, Reicin A, et al; for the VIGOR study group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
9. Finckh A, Aronson MD. Cardiovascular risks of cyclooxygenase-2 inhibitors: where do we stand now. Ann Intern Med. 2005;142:157-164.
10. US Food and Drug Administration. Alert for healthcare professionals: non-selective non-steroidal antiinflammatory drugs (NASIDs). http://www.fda.gov/cder/drug/InfoSheets/HCP/NS_NSAIDsHCP.htm. Accessed July 12, 2006.
11. European Medicines Agency. European Medicines Agency update on non-selective NSAIDs. http://www.emea.eu.int/pdfs/human/press/pr/29896405en.pdf. Accessed July 12, 2006.
12. European Medicines Agency. European Medicines Agency concludes action on COX-2 inhibitors. http://www.emea.eu.int/pdfs/human/press/pr/20776605en.pdf. Accessed July 12, 2006.
13. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. http://www.ohri.ca/programs/clinical_epidemiology/oxford_web.ppt. Accesssed July 12, 2006.
14. McGettigan P, Han P, Henry D. Cyclooxygenase-2 inhibitors and coronary occlusion: exploring dose-response relationships. Br J Clin Pharmacol. 2006;62:358. doi:10.1111/j.1365-2125.2006.02660.x.
15. Kimmel SE, Berlin JA, Reilly M, et al. The effects of non-selective non-aspirin non-steroidal antiinflammatory medications on the risk of non-fatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol. 2004;43:985-990.
16. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005;142:157-164.
17. Gíslason GH, Jacobsen S, Rasmussen J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906-2913.
18. Curtis JP, Wang Y, Portnay E, Masoudi F, Havranek E, Krumholz H. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ. 2003;327:1322-1323.
19. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-574.
20. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003;163:481-486.
21. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
22. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and the risk of serious coronary heart disease: an observational cohort study. Lancet. 2002;359:118-123.
23. Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient not the drug class. Ann Rheum Dis. 2005;64(suppl III):85.
24. Sturkenboom MCJM, Dieleman J, Verhamme K, Straus S, Vander Hoeven-Borgman M, van der Lei J. Cardiovascular events during use of COX-2 selective and non-selective NSAIDs. Pharmacoepidemiol Drug Saf. 2005;14:S57.
25. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalisation for myocardial infarction among users of rofecoxib, celecoxib and other NSAIDs: a population based case control study. Arch Intern Med. 2005;165:978-984.
26. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142:481-489.
27. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Current use of non-steroidal antiinflammatory drugs and risk of acute myocardial infarction. Pharmacotherapy. 2005;25:503-510.
28. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzales-Perez A. Non-steroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109:3000-3006.
29. Bak S, Andersen M, Tsiropoulos I, et al. Risk of stroke associated with non-steroidal antiinflammatory drugs. Stroke. 2003;34:379-386.
30. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162:1099-1104.
31. Schlienger RG, Jick H, Meier CR. Use of non-steroidal anti-inflammatory drugs and the risk of firsttime acute myocardial infarction. Br J Clin Pharmacol. 2002;54:327-332.
32. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105-1110.
33. Garcia Rodriguez LA, Varas-Lorenzo C, Patrono C. Differential effects of aspirin and non-aspirin non-steroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in post-menopausal women. Epidemiology. 2000;11:382-387.
34. Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ. 2006;174. doi:10.1503/cmaj.051679.
35. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CM. Discontinuation of non-steroidal antiinflammatory drug therapy and the risk of acute myocardial infarction. Arch Intern Med. 2004;164:2472-2476.
36. Garcia Rodriguez LA, Gonzalez-Perez A. Long-term use of traditional of non-steroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. BMC Med. 2005;3:17. doi:10.1186/1741-7015-3-17.
37. Ko D, Yang W, Berger A, Bradford M, Krumholz H. Non-steroidal anti-inflammatory drugs after acute myocardial infarction. Am Heart J. 2002;143:475-481.
38. Kimmel SE, Berlin J, Kinman J, et al. Parenteral ketorolac and risk of myocardial infarction. Pharmacoepidemiol Drug Saf. 2002;11:113-119.
39. Sudbo J, Lee JJ, Lippman S, et al. Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case control study [retracted in Lancet. 2006;367:382]. Lancet. 2005;366:1359-1366.
40. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [erratum]. N Engl J Med. 2006;355:221.
41. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021-2029.
42. Catella-Lawson F, Reily MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
43. Patrono C, Patrignani P, Garcia Rodriguez L. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108:7-13.
44. Morant SV, Pettitt D, MacDonald TM, et al. Application of a propensity score to adjust for channeling bias with NSAIDs. Pharmacoepidemiol Drug Saf. 2004;13:345-353.